RE: Timelines13 Jun 2020 21:47
BAMS is incremental and will help with capacity where needed, it won’t replace PCR by any stretch of the imagination. Genedrive might struggle in the U.K. due to existing contracts here and lower infection rates, but they now have a product ready for sale and I think they’ll due really well globally due to their unique freeze dried offering.
In fact, I liked their product so much I bought the company (or at least a very tiny bit of it). As I’ve said, in the short term I see more movement over there, with all gains being reinvested here. But now I’m doing that annoying thing of ramping another company. Maybe I’ll return the favour on their board, they were talking about their test being used in airports. No chance, that’s Awacta LFD territory. Plenty room for all...